The patients’ baseline characteristics are shown in Table 1; no significant difference was observed among the non-irAE group, uni-irAE group, and multi-irAEs group in terms of age, gender, ECOG score, TNM stage, family history, treatment lines, tumor site, tumor differentiation, treatment regimen, number of metastases, HER2 status, MMR status, and PD-L1 expression. This evidence concerns the gene ERBB2 and neoplasm.